Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26905282 | 0.84 | MAPT (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4431900 | 0.81 | MAPT (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL644838 | 0.79 | HDAC3 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2614365 | 0.79 | KDM4E (0.60) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3499089 | 0.79 | ALPL (0.57) | KDM4EHSD17B10GAANPC1MAPT | |
| SCHEMBL31324688 | 0.79 | ALPL (0.57) | KDM4EHSD17B10GAANPC1MAPT | |
| SCHEMBL17380794 | 0.77 | KDM4E (0.38) | KDM4EHSD17B10GAANPC1MAPT | |
| SCHEMBL17380985 | 0.77 | ADORA3 (0.41) | KDM4EHSD17B10GAANPC1MAPT | |
| SCHEMBL10971458 | 0.76 | IMPDH2 (0.42) | KDM4EHSD17B10GAANPC1ALDH1A1 | |
| SCHEMBL12591902 | 0.76 | MAPT (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5001227-A | Fibre-reactive 1:1 chromium complex azo or azomethine dyes having a bidentate chelating group and a monofunctional neutral ligand | CIBA-GEIGY CORPORATION (US) | 1991-03-19 | — | — | US | claimed |
| EP-3536692-B1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3536692-B1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3536692-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3173413-B1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10202389-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10202389-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| CN-104136399-B | The pyrazolopyrimidine base inhibitor of ubiquitin activating enzyme | 米伦纽姆医药公司 | 2018-08-07 | — | — | CN | disclosed |
| US-9969741-B2 | Pyrazolotriazines as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2018-05-15 | — | — | US | disclosed |
| US-9969741-B2 | Pyrazolotriazines as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2018-05-15 | — | — | US | disclosed |
| US-20100063051-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
| WO-2008057862-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-1534273-A4 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20050171136-A1 | Modulators of the glucocorticoid receptor and method | VACCARO WAYNE (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1534273-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | Bristol-Myers Squibb Company (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040132758-A1 | Modulators of the glucocorticoid receptor and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-08 | — | — | US | disclosed |
| WO-2004009017-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
| US-5001227-A | Fibre-reactive 1:1 chromium complex azo or azomethine dyes having a bidentate chelating group and a monofunctional neutral ligand | CIBA-GEIGY CORPORATION (US) | 1991-03-19 | — | — | US | disclosed |
| US-4185013-A | Anionic azo dyes having a 3-dibenzofuranyl diazo component radical optionally having a 2- or 8-sulfo group | SANDOZ LTD. (CH) | 1980-01-22 | — | — | US | disclosed |
| US-4081438-A | Anionic azo dyes having a 3-dibenzofuranyl diazo component radical optionally having A2-or 8-sulfo group | SANDOZ LTD. (CH) | 1978-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063051-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NFKB2, NFKBIA | HDAC3 467/4885HDAC4 920/4885HDAC1 269/4885 |
| US-10202389-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | UBA1, UBXN1, UBE2E1 | HDAC3 1020/4885HDAC4 1251/4885HDAC1 248/4885 |
| US-20040132758-A1 | Modulators of the glucocorticoid receptor and method | NR3C1, NR3C2, MC2R | HDAC3 507/4885HDAC4 849/4885HDAC1 724/4885 |
| US-20050171136-A1 | Modulators of the glucocorticoid receptor and method | NR3C1, MC2R, NR3C2 | HDAC3 656/4885HDAC4 744/4885HDAC1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.